Biopharma firm Atreca goes public

Redwood City, California-based Atreca Inc, a biopharmaceutical company, has raised about $113.8 million for its IPO after pricing its 7.35 million shares at $17 per share. The stock began trading June 20, 2019 on the NASDAQ under the ticker symbol “BCEL.” Cowen, Evercore ISI and Stifel are the lead underwriters. Atreca’s pre-IPO backers included Wellington Management Company LLC, Cormorant Asset Management, Aisling Capital, Boxer Capital of the Tavistock Group, EcoR1 Capital, Redmile Group, Samsara BioCapital and funds managed by Tekla Capital Management.

Read the press release